Donald M. Poretz

2.1k total citations
40 papers, 1.6k citations indexed

About

Donald M. Poretz is a scholar working on Pharmacology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Donald M. Poretz has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pharmacology, 15 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Donald M. Poretz's work include Antibiotics Pharmacokinetics and Efficacy (21 papers), Antibiotic Resistance in Bacteria (9 papers) and Antibiotic Use and Resistance (7 papers). Donald M. Poretz is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (21 papers), Antibiotic Resistance in Bacteria (9 papers) and Antibiotic Use and Resistance (7 papers). Donald M. Poretz collaborates with scholars based in United States, United Kingdom and Canada. Donald M. Poretz's co-authors include Lawrence J. Eron, Joseph A. Paladino, M. Schilling, Penelope Ward, Dávid Paár, Frederick G. Hayden, Robert L. Atmar, Les Huson, Roger Mills and Casey Johnson and has published in prestigious journals such as New England Journal of Medicine, JAMA and Clinical Infectious Diseases.

In The Last Decade

Donald M. Poretz

40 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald M. Poretz United States 21 648 580 445 250 184 40 1.6k
S. Hedderwick United Kingdom 21 1.0k 1.6× 223 0.4× 811 1.8× 176 0.7× 155 0.8× 43 2.0k
Joel Ruskin United States 18 994 1.5× 257 0.4× 609 1.4× 549 2.2× 52 0.3× 32 2.2k
Philip Toltzis United States 23 673 1.0× 149 0.3× 655 1.5× 185 0.7× 100 0.5× 86 1.6k
Barry Fox United States 22 652 1.0× 124 0.2× 269 0.6× 220 0.9× 152 0.8× 57 1.5k
H Grant Stiver Canada 23 599 0.9× 168 0.3× 300 0.7× 72 0.3× 59 0.3× 60 1.4k
Javier Ena Spain 24 610 0.9× 121 0.2× 630 1.4× 84 0.3× 119 0.6× 102 1.7k
Burt R. Meyers United States 27 750 1.2× 732 1.3× 671 1.5× 93 0.4× 62 0.3× 78 2.0k
Francisc Schlaeffer Israel 24 735 1.1× 209 0.4× 429 1.0× 224 0.9× 30 0.2× 80 2.0k
Patrick Lillie United Kingdom 12 875 1.4× 177 0.3× 434 1.0× 149 0.6× 70 0.4× 39 1.4k
Gregory Filice United States 28 994 1.5× 99 0.2× 606 1.4× 452 1.8× 57 0.3× 68 2.3k

Countries citing papers authored by Donald M. Poretz

Since Specialization
Citations

This map shows the geographic impact of Donald M. Poretz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald M. Poretz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald M. Poretz more than expected).

Fields of papers citing papers by Donald M. Poretz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald M. Poretz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald M. Poretz. The network helps show where Donald M. Poretz may publish in the future.

Co-authorship network of co-authors of Donald M. Poretz

This figure shows the co-authorship network connecting the top 25 collaborators of Donald M. Poretz. A scholar is included among the top collaborators of Donald M. Poretz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald M. Poretz. Donald M. Poretz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Poretz, Donald M.. (2018). Lipoglycopeptides, Outpatient Parenteral Antibiotic Therapy, and the Infectious Disease Doctor—Moving Forward. Infectious Diseases in Clinical Practice. 26(3). 121–122. 1 indexed citations
2.
Ledgerwood, Julie E., Zonghui Hu, Pamela Costner, et al.. (2015). Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemporary Clinical Trials. 44. 112–118. 11 indexed citations
3.
Wali, Ravinder K., Johann Jonsson, Donald M. Poretz, et al.. (2015). Acute Neurological Illness in a Kidney Transplant Recipient Following Infection With Enterovirus-D68: An Emerging Infection?. American Journal of Transplantation. 15(12). 3224–3228. 7 indexed citations
4.
Poretz, Donald M.. (2013). Commentary on “Group B Streptococcal Bacteremia in Adults in the 21st Century. Infectious Diseases in Clinical Practice. 21(2). 77–78. 1 indexed citations
5.
Mullane, Kathleen M., Drew J. Winston, M. S. Wertheim, et al.. (2013). Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults. The Journal of Infectious Diseases. 208(9). 1375–1385. 59 indexed citations
6.
Paladino, Joseph A. & Donald M. Poretz. (2010). Outpatient Parenteral Antimicrobial Therapy Today. Clinical Infectious Diseases. 51(S2). S198–S208. 132 indexed citations
7.
Hayden, Frederick G., Robert L. Atmar, M. Schilling, et al.. (1999). Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. New England Journal of Medicine. 341(18). 1336–1343. 384 indexed citations
8.
Mann, Lee S., et al.. (1999). Executive Functioning and Compliance in HIV Patients. Psychological Reports. 84(1). 319–322. 13 indexed citations
9.
Poretz, Donald M.. (1999). 1999 Guidelines for Infectious Diseases in Primary Care. Clinical Infectious Diseases. 29(2). 470–470. 1 indexed citations
10.
Tice, Alan D., et al.. (1998). Medicare Coverage of Outpatient Ambulatory Intravenous Antibiotic Therapy: A Program that Pays for Itself. Clinical Infectious Diseases. 27(6). 1415–1421. 15 indexed citations
11.
Poretz, Donald M.. (1994). Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery device: Global analysis of a large-scale, multicenter trial. The American Journal of Medicine. 97(2). 34–42. 9 indexed citations
12.
Poretz, Donald M.. (1994). Introduction. The American Journal of Medicine. 97(2). 1–2. 5 indexed citations
13.
Poretz, Donald M.. (1993). Infusion Center, Office, and Home. Hospital Practice. 28(sup2). 40–43. 9 indexed citations
14.
Poretz, Donald M.. (1991). Home Intravenous Antibiotic Therapy. Clinics in Geriatric Medicine. 7(4). 749–764. 42 indexed citations
15.
Poretz, Donald M.. (1991). The Infusion Center: A Model for Outpatient Parenteral Antibiotic Therapy. Clinical Infectious Diseases. 13(Supplement_2). S142–S146. 30 indexed citations
16.
Ingram, C. W., et al.. (1988). Antibiotic Therapy in Osteomyelitis in Outpatients. Medical Clinics of North America. 72(3). 723–738. 24 indexed citations
17.
Poretz, Donald M.. (1988). Home management of intravenous antibiotic therapy.. PubMed Central. 9 indexed citations
18.
Eron, Lawrence J., et al.. (1983). Ceftriaxone therapy of serious bacterial infections. Journal of Antimicrobial Chemotherapy. 12(1). 65–78. 21 indexed citations
19.
Poretz, Donald M.. (1982). Intravenous Antibiotic Therapy in an Outpatient Setting. JAMA. 248(3). 336–336. 130 indexed citations
20.
Poretz, Donald M., et al.. (1973). Clinical and Laboratory Evaluation of Amoxicillin (BRL 2333) in the Treatment of Urinary Tract Infections. Antimicrobial Agents and Chemotherapy. 4(1). 25–30. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Hedderwick Breakdown of academic impact, for papers by Joel Ruskin Breakdown of academic impact, for papers by Philip Toltzis Breakdown of academic impact, for papers by Barry Fox Breakdown of academic impact, for papers by H Grant Stiver Breakdown of academic impact, for papers by Javier Ena Breakdown of academic impact, for papers by Burt R. Meyers Breakdown of academic impact, for papers by Francisc Schlaeffer Breakdown of academic impact, for papers by Patrick Lillie Breakdown of academic impact, for papers by Gregory Filice
Rankless by CCL
2026